• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Its products include Omadacycline and Sarecycline. The company was founded in February 2001 and is headquartered in Boston, MA.
Market Cap | 8.451 Million | Shares Outstanding | 9.39 Million | Avg 30-day Volume | 59.268 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.19 |
Price to Revenue | 5.8932 | Debt to Equity | -2.4494 | EBITDA | -74.87 Million |
Price to Book Value | 0.0 | Operating Margin | -160.907 | Enterprise Value | 400.955 Million |
Current Ratio | 6.852 | EPS Growth | 0.443 | Quick Ratio | 5.882 |
1 Yr BETA | 0.3546 | 52-week High/Low | 0.0 / | Profit Margin | -205.7391 |
Operating Cash Flow Growth | 22.8438 | Altman Z-Score | -5.9917 | Free Cash Flow to Firm | -69.636 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BIGHAM MICHAEL EXEC. CHAIRMAN OF THE BOARD |
|
922,282 | 2021-08-16 | 1 |
HASKEL WILLIAM M. CLO, GENERAL COUNSEL & SEC. |
|
370,525 | 2021-08-16 | 1 |
LOH EVAN CEO |
|
1,000,360 | 2021-08-16 | 1 |
WOODROW ADAM PRESIDENT & CHIEF COMMERCIAL |
|
501,321 | 2021-08-16 | 1 |
BRENNER RANDALL B. CHIEF DEVELOPMENT & REGULATORY |
|
281,424 | 2021-08-16 | 1 |
|
30,000 | 2020-02-19 | 0 | |
|
26,625 | 2020-02-19 | 0 | |
|
30,000 | 2020-02-19 | 0 | |
|
21,000 | 2020-02-19 | 0 | |
|
23,250 | 2020-02-19 | 0 | |
|
35,000 | 2020-02-19 | 0 | |
PAGAN DOUGLAS W. CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2019-04-05 | 0 |
BIGHAM MICHAEL CHAIRMAN AND CEO BIGHAM MICHAEL CHAIRMAN AND CEO |
|
257,167 | 2018-10-02 | 1 |
|
No longer subject to file | 2015-05-28 | 0 | |
|
No longer subject to file | 2014-10-30 | 0 | |
OCLASSEN GLENN A PRESIDENT AND CEO |
|
No longer subject to file | 2014-10-30 | 0 |
|
No longer subject to file | 2014-10-30 | 0 | |
PATTERSON LEONE D VICE PRESIDENT, CFO |
|
No longer subject to file | 2014-10-30 | 0 |
|
No longer subject to file | 2014-10-30 | 0 | |
|
10,933,503 | 2014-10-30 | 0 | |
KOLLINS JOHN A SVP, CHIEF BUSINESS OFFICER |
|
No longer subject to file | 2014-10-30 | 0 |
|
No longer subject to file | 2014-10-30 | 0 | |
|
No longer subject to file | 2014-10-30 | 0 | |
SINGH NIKHILESH N SVP & CHIEF SCIENTIFIC OFFICER |
|
No longer subject to file | 2014-10-30 | 0 |
BOXMEYER KATHRYN M. SEE REMARKS |
|
0 | 2014-10-30 | 0 |
|
1,266,486 | 2014-10-30 | 0 | |
|
0 | 2014-10-30 | 0 | |
|
2,207,511 | 2013-12-13 | 0 | |
SOLOWAY THOMAS P EVP, CHIEF OPERATING OFFICER |
|
0 | 2013-07-15 | 0 |
|
0 | 2013-04-10 | 0 | |
WORTZMAN MARILYN E VP, FINANCE |
|
217 | 2012-04-16 | 0 |
|
0 | 2012-01-24 | 0 | |
KENNEDY JOSEPH T VP AND GENERAL COUNSEL |
|
0 | 2011-12-01 | 0 |
|
1,983,884 | 2011-09-21 | 0 | |
|
1,983,884 | 2011-09-21 | 0 | |
NEW LEAF VENTURE MANAGEMENT I, L.P. |
|
No longer subject to file | 2011-07-18 | 0 |
|
1,099,288 | 2011-03-29 | 0 | |
|
0 | 2011-02-02 | 0 | |
|
0 | 2011-02-02 | 0 | |
MOORE TERRENCE O VP, MARKETING AND SALES |
|
3,928 | 2011-02-02 | 0 |
KOPPY SUSAN VP, CORPORATE DEVELOPMENT |
|
0 | 2009-02-12 | 0 |
|
2,083,426 | 2009-01-30 | 0 | |
|
2,083,426 | 2009-01-30 | 0 | |
|
2,083,426 | 2009-01-30 | 0 | |
|
2,083,426 | 2009-01-30 | 0 | |
|
No longer subject to file | 2009-01-30 | 0 | |
|
2,083,426 | 2009-01-30 | 0 | |
|
2,083,426 | 2009-01-30 | 0 | |
|
No longer subject to file | 2009-01-30 | 0 | |
|
2,083,426 | 2009-01-30 | 0 | |
|
No longer subject to file | 2009-01-30 | 0 | |
|
9,289,794 | 2009-01-28 | 0 | |
|
9,289,794 | 2009-01-28 | 0 | |
|
67,875 | 2009-01-28 | 0 | |
|
2,907,523 | 2009-01-28 | 0 | |
|
9,289,794 | 2009-01-28 | 0 | |
|
9,289,794 | 2009-01-28 | 0 | |
ALBINI EDWARD C V.P., CHIEF FINANCIAL OFFICER |
|
18,897 | 2008-05-09 | 0 |
SINGH AMAR P CHF. COMMERCIALIZATION OFFICER |
|
8,741 | 2008-05-09 | 0 |
|
35,714 | 2008-02-13 | 0 | |
HEMBERGER JUDITH A |
|
0 | 2008-02-13 | 0 |
|
35,714 | 2008-02-13 | 0 | |
|
0 | 2008-02-13 | 0 | |
|
342,857 | 2008-02-13 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|